<DOC>
	<DOC>NCT02015520</DOC>
	<brief_summary>The primary purpose of this study is to identify an appropriate dose of study medication.</brief_summary>
	<brief_title>Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) [1987] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening ACR global functional status class of 1 to 3 Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1) Elevated Highsensitivity (hs) CRP and/or ESR Active serious infection History of or active tuberculosis (TB) Elevated liver function tests (LFTs)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>